Kiora receives IND approval for Phase 2 trial of KIO-301 in retinitis pigmentosa

KIORA PHARMACEUTICALS INC

ABACUS-2 is a 36-patient, multi-center, double-masked, randomized, controlled Phase 2 trial.
Enrolling patients with ultra-low vision or no light perception regardless of gene mutation.
First patient dosing expected next year after validation of novel functional vision endpoints.
KIO-301 is a light-sensitive small molecule photoswitch targeting retinal ganglion cells.
Primary endpoints include safety, tolerability; key efficacy: functional vision and visual acuity tests.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.